Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
November 13 2020 - 2:42PM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with
an extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced that Dr. Steven O’Day,
Executive Director of the John Wayne Cancer Institute, Dr. Jennifer
Buell, President and COO of Agenus, and Dr. Dhan Chand, Scientific
Director Head of Drug Discovery at Agenus, will participate in a
webcast hosted by Dr. Matt Phipps of William Blair on Monday,
November 16, 2020 at 10:00 a.m. ET.
Dr. Steven O’Day will review data of AGEN1181 from its ongoing
Ph1 dose escalation trial and discuss the initial responses,
particularly those in patients with microsatellite stable disease,
and how to place these data in context with other CTLA-4
antibodies. He will also discuss the potential implications of
demonstrated Treg depletion with AGEN1181.
Dr. Jennifer Buell and Dr. Dhan Chand of Agenus will be
available to discuss the next steps for AGEN1181 and indications
selected for expansion. They will also discuss data from other
programs presented at SITC, including first clinical data for
AGEN2373, a CD137 agonist, the demonstrated importance of
Fc-enhancement for TIGIT, and preclinical data for AgenT-797,
AgenTus’ iNKT cell therapy, which recently entered the clinic for
COVID-19.
Registration for the webinar can be done in advance at
https://williamblair.zoom.us/webinar/register/WN_b0mxF_6yTWaC3bOTmfiTig.
A replay will be available after the call on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the potential and anticipated next steps for
Agenus’ AGEN1181, AGEN2373, anti-TIGIT, and AgenT-797, as well as
the rest of its other pipeline assets. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:Agenus Inc. Caroline
Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024